4.5 Article

Epithelioid Malignant Peripheral Nerve Sheath Tumor Arising in a Schwannoma, in a Patient With Neuroblastoma-like Schwannomatosis and a Novel Germ line SMARCB1 Mutation

期刊

AMERICAN JOURNAL OF SURGICAL PATHOLOGY
卷 36, 期 1, 页码 154-160

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PAS.0b013e3182380802

关键词

malignant peripheral nerve sheath tumor; schwannoma; schwannomatosis; SMARCB1/INI1

资金

  1. NIH [CA46274]

向作者/读者索取更多资源

Epithelioid malignant peripheral nerve sheath tumors arising in preexisting schwannomas are extremely rare. We report an unusual example occurring in a patient with multiple schwannomas (schwannomatosis), all but 1 of which showed neuroblastoma-like histology. By immunohistochemistry, both the epithelioid malignant peripheral nerve sheath tumor and the schwannomas showed a complete loss of the Smarcb1 protein. Subsequent genetic evaluation revealed the presence of a novel germline mutation in the SMARCB1/INI1 gene in the patient and in 3 of her children, 2 of whom were diagnosed with atypical teratoid/rhabdoid tumors of the brain.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Clinical Neurology

Clinical Importance of Molecular Testing in Neuromuscular Choristomas

Andres A. Maldonado, Robert J. Spinner, Jodi M. Carter

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2022)

Article Pathology

Overlapping morphological, immunohistochemical and genetic features of superficial CD34-positive fibroblastic tumor and PRDM10-rearranged soft tissue tumor

Florian Puls, Jodi M. Carter, Nischalan Pillay, Thomas A. McCulloch, Vaiyapuri P. Sumathi, Pehr Rissler, Henrik Fagman, Magnus Hansson, Fernanda Amary, Roberto Tirabosco, Linda Magnusson, Jenny Nilsson, Adrienne M. Flanagan, Andrew L. Folpe, Fredrik Mertens

Summary: Superficial CD34-positive fibroblastic tumor (SCD34FT) is a soft tissue tumor with borderline malignancy, overlapping with PRDM10 gene fusions. The tumors are morphologically indistinguishable and predominantly express CADM3, making them likely to be considered a single entity, SCD34FT. Immunohistochemistry for CADM3, combined with characteristic morphological features, is valuable in diagnosing SCD34FT.

MODERN PATHOLOGY (2022)

Article Multidisciplinary Sciences

Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities

Nicola Cosgrove, Damir Vareslija, Stephen Keelan, Ashuvinee Elangovan, Jennifer M. Atkinson, Sinead Cocchiglia, Fiona T. Bane, Vikrant Singh, Simon Furney, Chunling Hu, Jodi M. Carter, Steven N. Hart, Siddhartha Yadav, Matthew P. Goetz, Arnold D. K. Hill, Steffi Oesterreich, Adrian Lee, Fergus J. Couch, Leonie S. Young

Summary: The authors conducted a comprehensive study on the molecular landscape of breast cancer brain metastases, focusing on different breast cancer subtypes. They identified homologous recombination deficiency as a significant therapeutic vulnerability. The study revealed distinct transcriptional programs enriched in brain metastases and identified important hub genes and functional processes associated with the disease.

NATURE COMMUNICATIONS (2022)

Article Oncology

Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor-Positive Breast Cancer

Lixuan Wei, Huanyao Gao, Jia Yu, Huan Zhang, Thanh Thanh L. Nguyen, Yayun Gu, Marie R. Passow, Jodi M. Carter, Bo Qin, Judy C. Boughey, Matthew P. Goetz, Richard M. Weinshilboum, James N. Ingle, Liewei Wang

Summary: Androgen receptor (AR) is expressed in the majority of estrogen receptor a-positive (ER+) breast cancers. The efficacy of AR-targeting therapies, including both AR agonists and AR inhibitors, is dependent on the levels of AR and ERa. ENZ functions as an ERa antagonist in low AR expression breast cancer, while RAD140 activates AR signaling and suppresses AR-high tumor growth. Overall, this study provides insights into the clinical application of AR-targeting therapy based on the AR/ER ratio in ER+ breast cancers.

CANCER RESEARCH (2023)

Article Multidisciplinary Sciences

PDJ amplicon in triple negative breast cancer

Alexander S. Roesler, Smriti Malasi, Lori Koslosky, Peter Hartmayer, Tammey J. Naab, Jodi M. Carter, David Zahrieh, David Hillman, Roberto A. Leon-Ferre, Fergus J. Couch, Matthew P. Goetz, Karen S. Anderson, Barbara A. Pockaj, Michael T. Barrett

Summary: We investigated the prevalence, prognostic value, and enrichment by chemotherapy of the PDJ amplicon in TNBC. Our findings demonstrate that the prevalence of PDJ amplicons in TNBC varies extensively and is associated with poor clinical outcomes.

SCIENTIFIC REPORTS (2023)

Article Oncology

Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast

Amy C. Degnim, Brittany L. Siontis, Safia K. Ahmed, Tanya L. Hoskin, Tina J. Hieken, James W. Jakub, Christian L. Baum, Courtney Day, Sarah E. Schrup, Lauren Smith, Jodi M. Carter, Tiffany M. Sae Kho, Katrina N. Glazebrook, Aparna Vijayasekaran, Scott H. Okuno, Ivy A. Petersen

Summary: This study evaluated the impact of trimodality treatment compared to monotherapy or dual therapy for radiation-associated angiosarcoma of the breast (RAASB) after prior breast cancer treatment. The study found that trimodality therapy demonstrated a higher rate of pathological complete response and improved 5-year recurrence-free survival, but had more surgical complications and toxic effects.

CLINICAL CANCER RESEARCH (2023)

Article Multidisciplinary Sciences

Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer

Jodi M. Carter, Saranya Chumsri, Douglas A. Hinerfeld, Yaohua Ma, Xue Wang, David Zahrieh, David W. Hillman, Kathleen S. Tenner, Jennifer M. Kachergus, Heather Ann Brauer, Sarah E. Warren, David Henderson, Ji Shi, Yi Liu, Heikki Joensuu, Henrik Lindman, Roberto A. Leon-Ferre, Judy C. Boughey, Minetta C. Liu, James N. Ingle, Krishna R. Kalari, Fergus J. Couch, Keith L. Knutson, Matthew P. Goetz, Edith A. Perez, E. Aubrey Thompson

Summary: The use of spatial immunobiomarker quantitation is being actively explored in the prognosis and prediction of therapy in triple-negative breast cancer (TNBC). In this study, high-plex quantitative digital spatial profiling was used to analyze the immune protein microenvironments in treatment-naive TNBC. The results show that immune protein profiles differ significantly in intraepithelial and adjacent stromal microenvironments, and the enrichment of certain immune proteins is associated with better outcomes, highlighting the importance of spatial microenvironments in predicting the prognosis of TNBC.

NATURE COMMUNICATIONS (2023)

Article Oncology

Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer The Phase 2 TBCRC041 Randomized Clinical Trial

Tufia C. Haddad, Vera J. Suman, Antonino B. D'Assoro, Jodi M. Carter, Karthik V. Giridhar, Brendan P. McMenomy, Katelyn Santo, Erica L. Mayer, Meghan S. Karuturi, Aki Morikawa, P. Kelly Marcom, Claudine J. Isaacs, Sun Young Oh, Amy S. Clark, Ingrid A. Mayer, Khandan Keyomarsi, Timothy J. Hobday, Prema P. Peethambaram, Ciara C. O'Sullivan, Roberto A. Leon-Ferre, Minetta C. Liu, James N. Ingle, Matthew P. Goetz

Summary: This randomized clinical trial found that adding fulvestrant to treatment with alisertib did not increase objective tumor response rates (ORRs) or progression-free survival (PFS) in endocrine-resistant metastatic breast cancer (MBC).

JAMA ONCOLOGY (2023)

Article Pathology

Frequency of HER2 protein overexpression and HER2 gene amplification in endometrial clear cell carcinoma

William R. Sukov, Jain Zhou, Katherine B. Geiersbach, Gary L. Keeney, Jodi M. Carter, J. Kenneth Schoolmeester

Summary: HER2 overexpression and gene amplification have been well established in several tumors, and HER2 targeted therapy may be effective in these cases. However, interpreting data regarding HER2 in clear cell endometrial carcinoma (CCC) is challenging due to various issues. A study of hysterectomy specimens from CCC patients showed that HER2 overexpression and amplification occur in a subset of cases, suggesting the potential benefit of HER2 targeted therapy in CCC patients.

HUMAN PATHOLOGY (2023)

Article Oncology

Noninvasive prediction of axillary lymph node breast cancer metastasis using morphometric analysis of nodal tumor microvessels in a contrast-free ultrasound approach

Giulia Ferroni, Soroosh Sabeti, Tasneem Abdus-Shakur, Lorenzo Scalise, Jodi M. Carter, Robert T. Fazzio, Nicholas B. Larson, Mostafa Fatemi, Azra Alizad

Summary: The study aims to develop a non-invasive ultrasound imaging technique for detecting metastatic axillary lymph nodes in breast cancer patients. The results show that this technique can identify metastatic lymph nodes by analyzing vessel morphology features and can improve diagnostic performance when combined with clinical information.

BREAST CANCER RESEARCH (2023)

Article Oncology

Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors

Xiaojia Tang, Kevin J. Thompson, Krishna R. Kalari, Jason P. Sinnwell, Vera J. Suman, Peter T. Vedell, Sarah A. McLaughlin, Donald W. Northfelt, Alvaro Moreno Aspitia, Richard J. Gray, Jodi M. Carter, Richard Weinshilboum, Liewei Wang, Judy C. Boughey, Matthew P. Goetz

Summary: This study compared pre- and post-chemotherapy TNBC tumor samples and identified biomarkers associated with post-chemotherapy recurrence. The gene expression patterns were significantly altered in the post-treatment samples, indicating potential mechanisms and treatment targets for post-chemotherapy recurrence.

BREAST CANCER RESEARCH (2023)

Article Clinical Neurology

PET imaging characteristics of neuromuscular choristoma and associated desmoid-type fibromatosis

Tomas Marek, Robert J. Spinner, Jodi M. Carter, Nikhil K. Murthy, Kimberly K. Amrami, Stephen M. Broski

Summary: Background: Neuromuscular choristoma is a rare peripheral nerve lesion characterized by abnormal presence of muscle within nerve. This study reports the FDG PET characteristics of NMC and NMC-DTF, and suggests that increased FDG activity within NMCs may be associated with subclinical NMC-DTF or NMC-DTF precursor tissue.

ACTA NEUROCHIRURGICA (2023)

Letter Genetics & Heredity

Letter to editor: Orofacial overgrowth with peripheral nerve enlargement and perineuriomatous pseudo-onion bulb proliferations is part of the PIK3CA-related overgrowth spectrum

Andres A. Maldonado, Robert J. Spinner, Jodi M. Carter, Christopher J. Klein

HUMAN GENETICS AND GENOMICS ADVANCES (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Ultrasound high-definition microvasculature imaging with novel quantitative biomarkers improves breast cancer detection accuracy

Redouane Ternifi, Yinong Wang, Juanjuan Gu, Eric C. Polley, Jodi M. Carter, Sandhya Pruthi, Judy C. Boughey, Robert T. Fazzio, Mostafa Fatemi, Azra Alizad

Summary: In this study, a new contrast-free ultrasound microvasculature imaging technique was developed and new quantitative biomarkers were extracted to differentiate between benign and malignant breast lesions. The accuracy in characterizing breast lesions was significantly improved compared to conventional ultrasound.

EUROPEAN RADIOLOGY (2022)

Article Oncology

Hybrid high-definition microvessel imaging/shear wave elastography improves breast lesion characterization

Juanjuan Gu, Redouane Ternifi, Nicholas B. Larson, Jodi M. Carter, Judy C. Boughey, Daniela L. Stan, Robert T. Fazzio, Mostafa Fatemi, Azra Alizad

Summary: The study aimed to improve breast lesion differentiation by combining HDMI, SWE, and clinical factors. The SWE-HDMI prediction model showed significantly higher accuracy in detecting malignancy compared to using SWE or HDMI alone. Through elastic net logistic regression model training and validation, the SWE-HDMI prediction model exhibited high sensitivity and specificity in identifying malignant breast lesions.

BREAST CANCER RESEARCH (2022)

暂无数据